» Articles » PMID: 10952401

Acute Taurodeoxycholate-induced Pancreatitis in the Rat is Associated with HyperCCKemia

Overview
Specialty Gastroenterology
Date 2000 Aug 22
PMID 10952401
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cholecystokinin (CCK) has been suggested to be involved in the development and course of acute pancreatitis. In the present study we measured plasma CCK concentrations in acute experimental pancreatitis (AEP) in the rat, and evaluated the role of circulating CCK levels on the initial pancreatic damage in pancreatitis.

Methods: Endogenous hyperCCKemia was induced by surgical biliodigestive shunt (BDS) and exogenous hyperCCKemia by infusion of CCK-8S. The CCK-A receptor antagonist devazepide was used to antagonize the effect of CCK. Pancreatitis was induced by pancreatic duct infusion of sodium taurodeoxycholate 4 wk after the BDS operation or 1 wk after the start of the infusions. Nonpancreatitic sham- and BDS-operated rats, respectively, were used as control animals as were groups of otherwise untreated rats with pancreatitis. The animals were sacrificed 6 h after induction of pancreatitis. Concentrations of CCK were determined in plasma as were protein and amylase levels in the pancreas and peritoneal exudates. The extent of pancreatic necroses was assessed microscopically.

Results: Pancreatitis caused an 11-20-fold increase of circulating CCK as measured after 6 h. In pancreatitic rats with induced hyperCCKemia, there was a further marked increase of plasma CCK. Pancreatic weight and edema, protein and amylase contents, and extent of necroses were the same regardless of the level of plasma CCK. Devazepide had no influence on the studied pancreatic parameters.

Conclusion: We conclude that acute taurodeoxycholate-induced pancreatitis in the rat is associated with elevated plasma CCK concentrations. There seems, however, not to be any correlation between the degree of hyperCCKemia and the extent of initial pancreatic damage.

Citing Articles

Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction.

Barrett T, Yan W, Freedman J, Lagaud G, Breitenbucher J, Shankley N Br J Pharmacol. 2008; 153(8):1650-8.

PMID: 18297100 PMC: 2438255. DOI: 10.1038/bjp.2008.44.

References
1.
Niederau C, Liddle R, Ferrell L, Grendell J . Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. J Clin Invest. 1986; 78(4):1056-63. PMC: 423760. DOI: 10.1172/JCI112661. View

2.
Niederau C, Borchard F, Luthen R, Niederau M . Early development of experimental biliary pancreatitis and its amelioration by CCK-receptor blockade. Hepatogastroenterology. 1996; 43(12):1442-53. View

3.
Lankisch P, WINCKLER K, Bokermann M, Schmidt H, Creutzfeldt W . The influence of glucagon on acute experimental pancreatitis in the rat. Scand J Gastroenterol. 1974; 9(8):725-9. View

4.
Ohlsson B, Axelson J, Sternby B, Rehfeld J, Ihse I . Time-course of the pancreatic changes following long-term stimulation or inhibition of the CCK-A receptor. Int J Pancreatol. 1995; 18(1):59-66. DOI: 10.1007/BF02825422. View

5.
Lange P, Pedersen T . Initial treatment of acute pancreatitis. Surg Gynecol Obstet. 1983; 157(4):332-4. View